Related Experiment Video

Updated: Jul 12, 2026

The bm12 Inducible Model of Systemic Lupus Erythematosus (SLE) in C57BL/6 Mice
12:04

The bm12 Inducible Model of Systemic Lupus Erythematosus (SLE) in C57BL/6 Mice

Published on: November 1, 2015

Systemic lupus erythematosus: Phase 2 trials to watch in 2026

Eric F Morand1, Sarah A Jones2

  • 1Centre for Inflammatory Disease, Monash University, Clayton, VIC, Australia; Rheumatology, Monash Health, Clayton, VIC, Australia.

Med (New York, N.Y.)
|July 10, 2026
PubMed

Insights

Clinical trials for systemic lupus erythematosus (SLE) are advancing in 2026. New trials focus on novel mechanisms, offering insights into SLE pathogenesis.

Area of Science:

  • Rheumatology
  • Immunology
  • Clinical Research

Background:

  • Systemic lupus erythematosus (SLE) is a complex autoimmune disease.
  • Current treatments aim to manage symptoms and reduce disease activity.
  • Understanding SLE pathogenesis is crucial for developing targeted therapies.

Purpose of the Study:

  • To provide an overview of ongoing clinical trials for SLE in 2026.
  • To highlight trials investigating novel therapeutic mechanisms.
  • To discuss the potential insights these trials may offer into SLE pathogenesis.

Main Methods:

  • Review of ongoing clinical trials for SLE.
  • Identification of trials targeting novel disease mechanisms.
  • Categorization of trials based on therapeutic targets and disease stage.

Main Results:

  • A significant number of SLE clinical trials are active in 2026.
  • Several trials are exploring innovative therapeutic targets beyond established pathways.
  • These novel trials represent a shift towards precision medicine in SLE treatment.

Conclusions:

  • The landscape of SLE clinical trials is dynamic and expanding.
  • Novel mechanistic trials hold promise for deeper understanding and improved SLE management.
  • Continued research is essential to translate these findings into clinical practice.

Related Concept Videos

Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
iPS Cell Differentiation01:22

iPS Cell Differentiation

The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
Nephrotic Syndrome II : Assessment and Medical Management01:26

Nephrotic Syndrome II : Assessment and Medical Management

IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document any history...